Current Report Filing (8-k)
September 21 2022 - 5:31PM
Edgar (US Regulatory)
0000910267
false
0000910267
2022-09-15
2022-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): September 15, 2022
Titan Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-13341 |
|
94-3171940 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
(Address
of principal executive offices and zip code)
650-244-4990
(Registrant’s
telephone number including area code)
(Registrant’s
former name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.001 par value |
|
TTNP |
|
Nasdaq Capital Market |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
September 15, 2022 (the “Grant Date”), the board of directors (the “Board”) of Titan Pharmaceuticals,
Inc., a Delaware corporation (the “Company” or “Titan”) granted to each of Avraham Ben-Tzvi, Peter L.
Chasey, Eric Greenberg, Matthew C. McMurdo, David Natan and Kate Beebe DeVarney, Ph.D., members of the Board, options (the “Options”)
to purchase 100,000 shares of the Company’s common stock at an exercise price of $1.31 per share, being the closing price
of the Company’s shares of common stock and the fair market value as defined under the Titan 2015 Omnibus Incentive Plan
(the “2015 Plan”) on the Grant Date. The Options have a term of ten years from the Grant Date, vesting in twelve equal
monthly allotments through the first anniversary of the Grant Date, and are conditioned only on the approval by the Company’s
stockholders of an increase in the authorized number of shares available for issuance under the 2015 Plan. In the event there
is a change of control (as defined under the 2015 Plan), any outstanding unvested Options will automatically vest and become exercisable
on the date of such change of control in accordance with the terms of the 2015 Plan.
Item
9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: September 21, 2022 |
TITAN PHARMACEUTICALS,
INC. |
|
|
|
|
By: |
/s/ David E. Lazar |
|
|
Name: |
David E. Lazar |
|
|
Title: |
Chief Executive Officer |
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Apr 2023 to Apr 2024